Correlation Between Ares Acquisition and Takeda Pharmaceutical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ares Acquisition and Takeda Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ares Acquisition and Takeda Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ares Acquisition and Takeda Pharmaceutical Co, you can compare the effects of market volatilities on Ares Acquisition and Takeda Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ares Acquisition with a short position of Takeda Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ares Acquisition and Takeda Pharmaceutical.

Diversification Opportunities for Ares Acquisition and Takeda Pharmaceutical

-0.76
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Ares and Takeda is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Ares Acquisition and Takeda Pharmaceutical Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Takeda Pharmaceutical and Ares Acquisition is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ares Acquisition are associated (or correlated) with Takeda Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Takeda Pharmaceutical has no effect on the direction of Ares Acquisition i.e., Ares Acquisition and Takeda Pharmaceutical go up and down completely randomly.

Pair Corralation between Ares Acquisition and Takeda Pharmaceutical

Considering the 90-day investment horizon Ares Acquisition is expected to generate 0.03 times more return on investment than Takeda Pharmaceutical. However, Ares Acquisition is 31.91 times less risky than Takeda Pharmaceutical. It trades about 0.18 of its potential returns per unit of risk. Takeda Pharmaceutical Co is currently generating about 0.0 per unit of risk. If you would invest  1,050  in Ares Acquisition on October 3, 2024 and sell it today you would earn a total of  6.00  from holding Ares Acquisition or generate 0.57% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy9.54%
ValuesDaily Returns

Ares Acquisition  vs.  Takeda Pharmaceutical Co

 Performance 
       Timeline  
Ares Acquisition 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ares Acquisition has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Ares Acquisition is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.
Takeda Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Takeda Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical indicators, Takeda Pharmaceutical is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Ares Acquisition and Takeda Pharmaceutical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ares Acquisition and Takeda Pharmaceutical

The main advantage of trading using opposite Ares Acquisition and Takeda Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ares Acquisition position performs unexpectedly, Takeda Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will offset losses from the drop in Takeda Pharmaceutical's long position.
The idea behind Ares Acquisition and Takeda Pharmaceutical Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Global Correlations
Find global opportunities by holding instruments from different markets